Ingenuity Systems Announces Molecular Toxicology Solution
Complete the form below to unlock access to ALL audio articles.
Ingenuity Systems has launched IPA-Tox™, a pathways-driven molecular toxicology solution that enables researchers to understand safety issues associated with new drug candidates.
Fully integrated within IPA 5.0, IPA-Tox provides user-friendly software tools that rapidly assess the toxicity and safety of compounds and includes new chemical content containing thousands of additional drugs and clinical candidates.
Ingenuity Pathways Analysis 5.0 (IPA) is a software application that enables researchers to model, analyze, and understand the complex biological systems at the core of life science research.
IPA is deployed in all major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports analysis of all experimental platforms, and is used at all stages of the drug discovery and development process, from target identification and validation to identification of biomarkers, predictive toxicology, and pharmacogenomics.
"We use IPA 5.0 in conjunction with targeted laser microdissection microarray analysis for high resolution mechanistic hypothesis generation in order to determine human toxicity from results in test species", said Dr. Ken Brown, Head of Molecular Biology, CXR Biosciences.
"Overlaying results from IPA with statistical clustering of microarray data provides new insights into the mechanisms of toxicological responses such as oxidative stress response, interactions of drugs with individual enzymes such as P450's, and xenobiotic metabolism. This is extremely useful for discovering biomarkers, determining toxicity in humans, and evaluating the utility of new toxicological models for risk assessment."
"We have listened to our customers and have incorporated their feedback regarding specific features and content to create IPA 5.0," commented Ramon Felciano, Chief Technology Officer of Ingenuity Systems.
"By maintaining an open dialogue with the research community, we are able to deliver software that meets the needs of both biologists and bioinformaticians. To date, IPA has been cited in more than 300 published research papers and is now used by every major pharmaceutical company in the world. We see this accomplishment as a validation of our value to researchers in the R&D process."